Showing 5751-5760 of 10175 results for "".
- Research Grant Supports Animal-Free Testing for Botoxhttps://practicaldermatology.com/news/research-grant-supports-animal-free-testing-botox/2462979/The National Center for Advancing Translational Services (NCATS) and the US Food and Drug Administration (FDA) awarded a $2 million research grant to develop an advanced testing platform capable of assessing the potency of botulinum toxin without the need for animal testing, according to a press
- Acne Vulgaris Market Projected to Eclipse $10 Billion by 2034https://practicaldermatology.com/news/acne-vulgaris-market-projected-eclipse-10-billion-2034/2462961/The acne vulgaris market reached a value of US$ 7.0 Billion in 2023 and is anticipated to grow at a CAGR of 3.23% to more than $10 billion by 2034, according to a report by the IMARC Group. The rising popularity of light-based and laser therapies is partially responsible for this growth,
- Study: OTC Ointment Effective for Hydration and Wound Healing after Dermatologic Procedureshttps://practicaldermatology.com/news/otc-ointment-effective-hydration-wound-headling-dermatologic-procedures/2462940/Results from a two-study analysis in the Journal of Drugs in Dermatology suggested efficacy for an over-the-counter healing ointment (HO; Cetaphil Healing Ointment, Galderma Laboratories, LP, Dallas) in improving skin hydration and wound healing outcomes following dermatologic procedures
- Trifarotene Plus Skincare Effective Treatment for Acne-Induced Hyperpigmentationhttps://practicaldermatology.com/news/trifarotene-plus-skincare-effective-treatment-acne-induced-hyperpigmentation/2462920/Trifarotene combined with a skincare regimen was effective for the treatment of acne-induced hyperpigmentation (AIH) accompanying acne vulgaris (AV), according to results from a recent phase IV double-blind study. Researc
- FDA Accepts sNDA for Dermavant's Tapinarof Cream, 1%https://practicaldermatology.com/news/tapinarof-1-cream-progresses-toward-approval-pediatric-eczema/2462895/The U.S. Food and Drug Administration (FDA) has accepted Dermavant's Supplemental New Drug Application (sNDA) for tapinarof cream, 1% (VTAMA®), for the treatment of atopic dermatitis in (AD), according to a news release from the manufacturer. The FDA assigned a Prescription Drug User Fee
- La Roche-Posay Unveils New Serum to Combat Dark Spotshttps://practicaldermatology.com/news/la-roche-posay-unveils-new-serum-combat-dark-spots/2462880/La Roche-Posay has announced the launch of its Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30 products. Powered by Melasyl™, the manufacturer said in a news release, L'Oreal's multi-patented ingredient derived from 18 years of research, represents "a breakthrough in pig
- LEVEL UP: Upadacitinib Shows Superior Efficacy in ADhttps://practicaldermatology.com/news/level-study-upadacitinib-shows-superior-efficacy-ad/2462870/New topline results evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable suggested that treatment with the drug was effective.<
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru
- Study Shows Pediatric Skin Diseases Have Hidden Impact on Mental Healthhttps://practicaldermatology.com/news/study-shows-pediatric-skin-diseases-have-hidden-impact-mental-health/2462858/New research unveils the hidden impact on mental health that some chronic skin conditions take for pediatric patients. The cross-sectional study, published in JAMA Dermatology, was conducted across 32 pediatric dermatology centers in the United States and Canada and aimed to expl
- Abrocitinib Cost-Effective Compared to Standard of Care for Atopic Dermatitis Treatment: Studyhttps://practicaldermatology.com/news/abrocitinib-cost-effective-compared-standard-care-atopic-dermatitis-treatment-japan/2462838/New research from a study of Japanese patients suggests that abrocitinib showed superior efficacy and safety compared to the standard of care (SoC). Recent findings from the JAK-1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials have unveiled promising insights into th